2016 American Transplant Congress
Microarray Analysis of Transbronchial and Mucosal Biopsies in Lung Transplant Recipients Detects Molecular Changes of T-Cell Mediated Inflammation.
Purpose: The main diagnostic platform for rejection in lung transplant recipients is histology of transbronchial biopsies (TBB), a test with a poor performance and safety…2016 American Transplant Congress
Machine Perfusion (MP) at 21[deg]C Simulates Hibernation Metabolic Pathways in a Non-Hibernator Mammal.
University of Pittsburgh, Pittsburgh.
Background: Hibernation is a complex and multi stage process that leads to unique metabolic changes over an extended period of time. Regulatory genes and transcription…2016 American Transplant Congress
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.
Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…2016 American Transplant Congress
Circulating Angiotensin II Receptor: Possible Marker for Antibody Mediated Tissue Injury?
Transplant Surgery, VCU Health, Richmond, VA.
Background. Antibody mediated rejection is the leading cause of renal allograft failure. Membrane-bound angiotensin II receptor(AngII) in the renal allograft can be a target of…2016 American Transplant Congress
Levels of VEGF-C, PLGF and Follistatin at 12 Months Post Transplantation Are Associated with Increased Risk for Long Term Progressive Renal Dysfunction.
*contributed equallyIntroduction Integrity of the microvasculature is critical for long term survival after solid organ transplantation. We hypothesize that biomarkers of endothelial injury and repair…2016 American Transplant Congress
Subtype-Compatible (A2/A2B–>B) Transplantation Under KAS Increases Access 3-Fold for Blood Type B Patients, yet Very Few Candidates Are Listed as Eligible.
Background: Prior to the new kidney allocation system (KAS; 12/4/14), 8 OPOs participated in a voluntary policy variance permitting allocation of kidneys from subtype “A2”…2016 American Transplant Congress
Safety of a Short (One-Year) Waiting Time in Kidney Transplant Candidates Treated for Cancer.
In Norway, a one-year waiting time free of cancer recurrence is required before kidney transplantation. To provide an updated, large-scale assessment of this practice, the…2016 American Transplant Congress
Analysis of FSGS (Focal Segmental Glomerulosclerosis) Recurrence After Renal Transplantation.
Nephrology-Division, Hospital do Rim - UNIFESP, São Paulo, Brazil.
Purpose: To describe clinical-laboratorial profile and outcome of patients diagnosed with recurrent FSGS submitted to plasmapheresis.Methods: Retrospective single-center cohort study including all patients with recurrent…2016 American Transplant Congress
Does DCD Donor Time-to-Death After Withdrawal of Support Affect Recipient Outcomes? Implications of Time-to-Death at a High-Volume Center in the United States.
Surgery, University of Wisconsin, Madison, WI.
Introduction: Donation after circulatory death (DCD) kidneys represent 15% of the deceased donor kidneys transplanted in the United States. A majority of transplant centers will…2016 American Transplant Congress
Effect of Complement Inhibition Therapy (Eculizumab) in Patients with C1q-Binding Donor-Specific Anti-HLA Antibodies: A Molecular Appraisal.
Complement-binding anti-HLA DSA have demonstrated higher rejection rate and decreased allograft outcome. We investigated the effect of terminal complement inhibition (Eculizumab) in a cohort of…
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 180
- Next Page »